ABVC News and Press, ABVC BioPharma Inc. From 08/11/21

CohBar (NASDAQ:CWBR) +62% on Q2 earnings Good Times Restaurant (NASDAQ:GTIM) +32% on Q3 earnings Upstart Holdings (NASDAQ:UPST) +22% on Q2 earnings Mogo (NASDAQ:MOGO) +20% on Q2 earnings fuboTV (NYSE:FUBO) +16% on Q2 earnings Lantern Pharma (N...

WallachBeth Capital Announces the Completion of an Underwritten Public Offering of 1,100,000 Units for ABVC BioPharma, Inc. PR Newswire JERSEY CITY, N.J. , Aug. 6, 2021 /PRNewswire/ -- WallachBeth Capital, a leading provider of capital markets and institutio...

FREMONT, CA, Aug. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system (CNS), and ophthalmology, today announced the pricing of its fir...

American BriVision holds key differentiators via novel botanical treatment solutions in key end markets. 2 of the company's candidates have the potential to fulfil a wide treatment void. The company filed an S-1 prospectus on November 23rd. We see a fair value of $34 - $140, d...

FREMONT, CA, Jan. 06, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- American BriVision (Holding) Corporation (OTCQB: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system (CNS), and ophthalmology, yesterd...

Issuing a clinical study report of the Phase II Part I clinical trial for ABV-1505 in adult Attention-Deficit Hyperactivity Disorder, the clinical-stage biopharma company, American BriVision (ABVC) said it expected to commence the Phase II Part II trial in Q2 2021.Following encourag...

·       PDC-1421, the active ingredient of ABV-1505, is being expanded into adult ADHD trials following encouraging Phase II trial results in major depressive disorder (MDD) ·       Phase II Part I trial of ABV-1505 has b...

FREMONT, CA, Sept. 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American BriVision (Holding) Corporation (OTCQB: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today issued a full clinical stud...

FREMONT, CA, Aug. 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE ‒ American BriVision (Holding) Corporation (OTCQB: ABVC) (the “Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today an...

· Last patient last visit (LPLV) marked the final step toward the completion of ABV-1505 Phase II Part I clinical trial in treatment of adult attention-deficit hyperactivity disorder (ADHD). · Preliminary Phase II Part I results indicated effective dosage and treatmen...